ECO 2026 Curtain-Raiser: 21-Expert Global Panel to Propose 10-Year GLP-1 Cancer Prevention Trial at Istanbul Congress (May 12–15)
Ahead of the European Congress on Obesity in Istanbul (May 12–15), a 21-expert global panel of obesity and cancer specialists will present a research proposal for a 10-year prospective trial testing GLP-1 receptor agonists like semaglutide and tirzepatide for prevention of obesity-related cancers. The proposal builds on the SELECT trial's established cardiovascular benefit, real-world dementia-incidence reductions, and the broader case that GLP-1s influence multiple aging-driven disease categories. The Istanbul meeting is the same venue where Novo Nordisk will present 52 abstracts on Wegovy, the higher-dose 7.2 mg formulation, the Wegovy pill, and CagriSema, including data on women's obesity, perimenopause, and migraine.